Rainbow Seed Fund appoints Romanos as consultant venture partner
British government-backed and Midven-managed biotech investor Rainbow Seed Fund has appointed Mike Romanos as consultant venture partner.
Romanos recently left his position as CEO of UK biotech Crescendo Biologics, which was backed by Rainbow Seed Fund, in addition to other institutional investors including Imperial Innovations, Astellas Venture Management and Sofinnova Partners.
Prior to joining Crescendo, Romanos spent 14 years with GlaxoSmithKline, leaving his role as vice-president of discovery technology in 2009.
The appointment of Romanos comes shortly after Rainbow Seed Fund invested in UK gene therapy company Quethera alongside co-investor Cambridge Enterprise.
More on People
CapMan Managing Partner Johan Pålsson to depart
Pålsson resigns from management effective immediately; to stay as buyout partner until February 2024
Capvis grapples with EUR 1bn fundraise amid team exodus
Five partners for the Swiss-based GP leave firm in last two years; sponsor started sixth buyout fundraise in early 2023
Golding adds insurance expertise with hire for institutional clients team
Tim Ickenroth joins as director with prior experience at BNP Paribas and UniCredit
Travers Smith bolsters funds practice with hire from Proskauer
Tosin Adeyeri joins with particular experience in secondary portfolio transactions
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater